Access the full text.
Sign up today, get DeepDyve free for 14 days.
M Kocher, R Soffietti, U Abacioglu, S Villa, F Fauchon, BG Baumert, L Fariselli, T Tzuk-Shina, RD Kortmann, C Carrie, M Ben Hassel, M Kouri, E Valeinis, D Berge, S Collette, L Collette, RP Mueller (2011)
Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952–26001 studyJ Clin Oncol, 29
R. Soffietti, M. Kocher, U. Abacioglu, S. Villà, F. Fauchon, B. Baumert, L. Fariselli, T. Tzuk-Shina, R. Kortmann, C. Carrie, M. Hassel, M. Kouri, E. Valeinis, D. Berge, R. Mueller, G. Tridello, L. Collette, A. Bottomley (2013)
A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 1
Peter Austin, Douglas Lee, Jason Fine (2016)
Introduction to the Analysis of Survival Data in the Presence of Competing RisksCirculation, 133
R. Prabhu, A. Dhabaan, W. Hall, T. Ogunleye, I. Crocker, W. Curran, H. Shu (2013)
Clinical outcomes for a novel 6 degrees of freedom image guided localization method for frameless radiosurgery for intracranial brain metastasesJournal of Neuro-Oncology, 113
L. Halasz, J. Weeks, B. Neville, N. Taback, R. Punglia (2013)
Use of stereotactic radiosurgery for brain metastases from non-small cell lung cancer in the United States.International journal of radiation oncology, biology, physics, 85 2
D. Altman, P. Royston (2000)
What do we mean by validating a prognostic model?Statistics in medicine, 19 4
E. Shaw, C. Scott, L. Souhami, R. Dinapoli, R. Kline, J. Loeffler, N. Farnan (2000)
Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05.International journal of radiation oncology, biology, physics, 47 2
H. Aoyama, H. Shirato, M. Tago, K. Nakagawa, T. Toyoda, K. Hatano, M. Kenjyo, N. Oya, S. Hirota, H. Shioura, E. Kunieda, T. Inomata, K. Hayakawa, N. Katoh, Gen Kobashi (2007)
Stereotactic Radiosurgery Plus Whole-Brain Radiation Therapy vs Stereotactic Radiosurgery Alone for Treatment of Brain Metastases: A Randomized Controlled TrialYearbook of Medicine, 2007
S. Berry, L. Ngo, E. Samelson, D. Kiel (2010)
Competing Risk of Death: An Important Consideration in Studies of Older AdultsJournal of the American Geriatrics Society, 58
P. Brown, K. Jaeckle, K. Ballman, E. Farace, J. Cerhan, S. Anderson, X. Carrero, F. Barker, R. Deming, S. Burri, C. Ménard, C. Ménard, C. Chung, V. Stieber, B. Pollock, E. Galanis, J. Buckner, A. Asher (2016)
Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial.JAMA, 316 4
E. Chang, J. Wefel, K. Hess, P. Allen, F. Lang, D. Kornguth, R. Arbuckle, J. Swint, A. Shiu, M. Maor, C. Meyers (2009)
Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial.The Lancet. Oncology, 10 11
G. Rodrigues, A. Warner, J. Zindler, B. Slotman, F. Lagerwaard (2014)
A clinical nomogram and recursive partitioning analysis to determine the risk of regional failure after radiosurgery alone for brain metastases.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 111 1
E. Steyerberg, K. Moons, D. Windt, J. Hayden, P. Perel, S. Schroter, R. Riley, H. Hemingway, D. Altman (2013)
Prognosis Research Strategy (PROGRESS) 3: Prognostic Model ResearchPLoS Medicine, 10
R. Press, R. Prabhu, D. Nickleach, Yuan Liu, H. Shu, S. Kandula, K. Patel, W. Curran, I. Crocker (2015)
Novel risk stratification score for predicting early distant brain failure and salvage whole‐brain radiotherapy after stereotactic radiosurgery for brain metastasesCancer, 121
T. Mekhail, Michael Sombeck, R. Sollaccio (2011)
Adjuvant Whole-Brain Radiotherapy Versus Observation after Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 StudyCurrent Oncology Reports, 13
D. Altman, Y. Vergouwe, P. Royston, K. Moons (2009)
Prognosis and prognostic research: validating a prognostic modelBMJ : British Medical Journal, 338
K. Patel, S. Burri, A. Asher, I. Crocker, R. Fraser, Chao Zhang, Zhengjia Chen, S. Kandula, J. Zhong, R. Press, J. Olson, N. Oyesiku, S. Wait, W. Curran, H. Shu, R. Prabhu (2016)
Comparing Preoperative With Postoperative Stereotactic Radiosurgery for Resectable Brain Metastases: A Multi-institutional Analysis.Neurosurgery
D. Ayala-Peacock, A. Peiffer, J. Lucas, S. Isom, J. Kuremsky, J. Urbanic, J. Bourland, A. Laxton, S. Tatter, E. Shaw, M. Chan (2014)
A nomogram for predicting distant brain failure in patients treated with gamma knife stereotactic radiosurgery without whole brain radiotherapy.Neuro-oncology, 16 9
M. Wolkewitz, B. Cooper, M. Bonten, A. Barnett, M. Schumacher (2014)
Interpreting and comparing risks in the presence of competing eventsBMJ : British Medical Journal, 349
R. D'Agostino, B. Nam (2003)
Evaluation of the Performance of Survival Analysis Models: Discrimination and Calibration Measures
Patients treated with stereotactic radiosurgery (SRS) for brain metastases (BM) are at increased risk of distant brain failure (DBF). Two nomograms have been recently published to predict individualized risk of DBF after SRS. The goal of this study was to assess the external validity of these nomograms in an independent patient cohort. The records of consecutive patients with BM treated with SRS at Levine Cancer Institute and Emory University between 2005 and 2013 were reviewed. Three validation cohorts were generated based on the specific nomogram or recursive partitioning analysis (RPA) entry criteria: Wake Forest nomogram (n = 281), Canadian nomogram (n = 282), and Canadian RPA (n = 303) validation cohorts. Freedom from DBF at 1-year in the Wake Forest study was 30% compared with 50% in the validation cohort. The validation c-index for both the 6-month and 9-month freedom from DBF Wake Forest nomograms was 0.55, indicating poor discrimination ability, and the goodness-of-fit test for both nomograms was highly significant (p < 0.001), indicating poor calibration. The 1-year actuarial DBF in the Canadian nomogram study was 43.9% compared with 50.9% in the validation cohort. The validation c-index for the Canadian 1-year DBF nomogram was 0.56, and the goodness-of-fit test was also highly significant (p < 0.001). The validation accuracy and c-index of the Canadian RPA classification was 53% and 0.61, respectively. The Wake Forest and Canadian nomograms for predicting risk of DBF after SRS were found to have limited predictive ability in an independent bi-institutional validation cohort. These results reinforce the importance of validating predictive models in independent patient cohorts.
Journal of Neuro-Oncology – Springer Journals
Published: Dec 7, 2017
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.